EMA Authorised: Temodal (temozolomide) — Merck Sharp & Dohme B.V.

View source ↗

Summary

Temodal (temozolomide) has been authorised in the EU for glioma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma

Drugs mentioned

• Temodal (temozolomide)

Snippet

Status: Authorised. Therapeutic area: Glioma. MAH: Merck Sharp & Dohme B.V.. Decision date: 03/06/2026